Gain Therapeutics’ (GANX) Preclinical Momentum Drives Its Progress in Parkinson’s Drug Development
GT-02287, a small molecule, focuses on treating Parkinson’s disease (PD) by restoring the function of glucocerebrosidase (GCase). GCase is an enzyme impaired in PD due to GBA1 mutations.




